<div>Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.</div>